![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » MYLAN'S GENERIC EFFEXOR GRANTED TENTATIVE APPROVAL
MYLAN'S GENERIC EFFEXOR GRANTED TENTATIVE APPROVAL
August 15, 2006
Mylan Laboratories announced that the FDA has granted tentative approval to its abbreviated new drug application for venlafaxine hydrochloride tablets 25 mg, 37.5 mg, 50 mg, 75 mg and 100 mg.
Venlafaxine is indicated for the treatment of major depressive disorder. The drug is the AB-rated generic version of Wyeth's Effexor Tablets, which had annual U.S. sales of approximately $154 million for the 12 months ending June 30.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct